Deciphera Pharmaceuticals LLC (DCPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Deciphera Pharmaceuticals LLC (DCPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7973
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Deciphera Pharmaceuticals LLC (Deciphera Pharmaceuticals) is a research and development company that develops, designs, and commercializes kinase inhibiting drugs. The company provides clinical pipeline of kinase inhibitors such as tumor-targeted therapies and immuno-targeted therapies. It uses proprietary switch control inhibitor platform for discovering and developing kinase inhibitors. Deciphera Pharmaceuticals products are used in the treatment of renal and colon cancers, mastocytosis, gastrointestinal stromal tumors, crohn’s disease and autoimmune nephritis, solid tumors and rheumatoid arthritis, among others. The company’s products are used in the treatment of immunological diseases and cancers. It markets its products through medical representatives. Deciphera Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Deciphera Pharmaceuticals LLC (DCPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Equity Offering 16
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC – Key Competitors 21
Deciphera Pharmaceuticals LLC – Key Employees 22
Deciphera Pharmaceuticals LLC – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Deciphera Pharmaceuticals announces second quarter 2018 financial results 24
May 08, 2018: Deciphera Pharmaceuticals Announces First Quarter 2018 Financial Results 26
Mar 28, 2018: Deciphera Pharmaceuticals Announces Fourth Quarter 2017 Financial Results and Corporate Highlights 27
Nov 14, 2017: Deciphera Pharmaceuticals Announces Third Quarter 2017 Financial Results and Corporate Highlights 29
Corporate Communications 30
May 29, 2018: Deciphera Pharmaceuticals Names Stephen B. Ruddy As Chief Technical Officer 30
May 21, 2018: Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director 31
Product News 32
11/06/2017: Deciphera Pharmaceuticals to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 32
Product Approvals 33
Nov 28, 2017: Deciphera Pharmaceuticals Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors 33
Sep 05, 2017: Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma 34
Clinical Trials 35
Jan 04, 2018: Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS study”) 35
Nov 20, 2017: Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology 36
Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 37
Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress 38
Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress 39
Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 40
May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting 41
Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 9
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Deciphera Pharma Raises USD52 Million in series C Financing 11
Deciphera Pharma Raises USD15 Million in Extended Series B Financing 12
Deciphera Pharma Raises USD75 Million in Series B Financing Round 13
Deciphera Pharma Raises USD21.5 Million in Financing Round 14
Deciphera Pharma Raises USD90.6 Million in Financing Round 15
Deciphera Pharma Plans to Raise up to USD400 Million in Public Offering of Securities 16
Deciphera Pharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD198 Million 17
Deciphera Pharma Raises USD127.5 in IPO 19
Deciphera Pharmaceuticals LLC, Key Competitors 21
Deciphera Pharmaceuticals LLC, Key Employees 22
Deciphera Pharmaceuticals LLC, Other Locations 23

List of Figures
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Deciphera Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Deciphera Pharmaceuticals LLC (DCPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CK Infrastructure Holdings Ltd (1038):石油・ガス:M&Aディール及び事業提携情報
    Summary CK Infrastructure Holdings Limited (CKI), a subsidiary of CK Hutchison Holdings Limited, is an infrastructure investment company. It holds diversified investment interests across various sectors including energy, rail transportation, water, waste management, and other infrastructure related …
  • Hyundai Engineering & Construction Co Ltd (000720):企業の財務・戦略的SWOT分析
    Hyundai Engineering & Construction Co Ltd (000720) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Vectrus Inc (VEC):企業の財務・戦略的SWOT分析
    Vectrus Inc (VEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Centra Industries, Inc.:企業の戦略・SWOT・財務情報
    Centra Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Centra Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Onorach Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient …
  • Shin-Etsu Chemical Co Ltd (4063):企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • HighCom Global Security, Inc.:企業の戦略・SWOT・財務分析
    HighCom Global Security, Inc. - Strategy, SWOT and Corporate Finance Report Summary HighCom Global Security, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • General Insurance Corporation of India:企業の戦略・SWOT・財務情報
    General Insurance Corporation of India - Strategy, SWOT and Corporate Finance Report Summary General Insurance Corporation of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務情報
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066)-医療機器分野:企業M&A・提携分析
    Summary Shandong Weigao Group Medical Polymer Company Ltd (Weigao) researches, develops, manufactures and sells disposable medical consumables, orthopedic materials and blood purification products. Its products include infusion sets, needles, blood bags, heart eluting stents, blood sampling products …
  • Cheng Shin Rubber Ind. Co Ltd (2105):企業の財務・戦略的SWOT分析
    Cheng Shin Rubber Ind. Co Ltd (2105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • JP Elektroprivreda BiH d.d. Sarajevo (JPESR):企業の財務・戦略的SWOT分析
    JP Elektroprivreda BiH d.d. Sarajevo (JPESR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Trevena Inc (TRVN)-製薬・医療分野:企業M&A・提携分析
    Summary Trevena Inc (Trevena) is a biopharmaceutical company that discovers and develops G-protein coupled receptor targeted medicines. The company’s products include RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination with …
  • Dynatronics Corp (DYNT):企業の財務・戦略的SWOT分析
    Summary Dynatronics Corp (Dynatronics) is a medical device company that offers physical therapy, aesthetics and medical products. The company offers hot and cold therapy, clinical accessories, body positioning, sports medicine, orthopedics, hand therapy, strength equipment, treatment tables and reha …
  • QRxPharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary QRxPharma Ltd (QRxPharma) develops and commercializes treatments for pain management and abuse prevention products. The company’s product portfolio includes late and early stage clinical drug candidates. Its dual opioid product portfolio includes Moxduo IR (Q8003), an immediate release oral …
  • Mitsubishi Logistics Corporation (9301):企業の財務・戦略的SWOT分析
    Mitsubishi Logistics Corporation (9301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • SimCorp AS (SIM):企業の財務・戦略的SWOT分析
    SimCorp AS (SIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mainstream Renewable Power Ltd-エネルギー分野:企業M&A・提携分析
    Summary Mainstream Renewable Power Ltd (Mainstream) develops, finances, constructs, and operates large-scale renewable energy plants. It develops and builds onshore and offshore wind and solar power plants. The company sells the plants to its natural owners including utilities, energy intensive corp …
  • Avantis Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Avantis Medical Systems Inc (AMS) is a medical device company that provides visualization technology solutions. The company provides products such as single camera colonoscopy devices and third eye panoramic devices. Its third eye panoramic devices provide two side-viewing cameras supplement …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆